Motley Fool |
3 Clinical-Stage Biotech Stocks with Explosive Upside Potential in 2015
Motley Fool Biotech stocks have the uncanny ability to absolutely crush it following a positive clinical or regulatory catalyst. And this trend has been especially pronounced among standout clinical-stage companies over the past few years. In 2014, for instance … |